Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 8/20 | 0.37 |
| ▸ | HTR2C | P28335 | 8/20 | 0.37 |
| ▸ | HTR2B | P41595 | 6/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3116407 | 0.92 | IRAK4 (0.38) | SYKAURKBIRAK4KCNH2HTR2A | |
| SCHEMBL906007 | 0.86 | CHRNB4 (0.53) | CHRNB4CHRNA3 | |
| SCHEMBL7055867 | 0.86 | CHRNB4 (0.53) | CHRNB4CHRNA3 | |
| SCHEMBL905805 | 0.86 | HTR2C (0.42) | KCNH2HTR2AHTR2CHTR2BCHRNB4 | |
| SCHEMBL2639684 | 0.86 | HTR2C (0.42) | KCNH2HTR2AHTR2CHTR2B | |
| SCHEMBL237951 | 0.86 | HTR2C (0.42) | KCNH2HTR2AHTR2CHTR2B | |
| SCHEMBL6181243 | 0.85 | CHRNB4 (0.45) | KCNH2HTR2AHTR2CHTR2BCHRNB4 | |
| SCHEMBL4313537 | 0.85 | HTR2C (0.42) | KCNH2HTR2AHTR2CHTR2BCHRNB4 | |
| SCHEMBL2639295 | 0.85 | HTR2C (0.42) | KCNH2HTR2AHTR2CHTR2BCHRNB4 | |
| SCHEMBL906026 | 0.84 | HTR2C (0.42) | KCNH2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513831-B1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB PUBL (SE) | 2010-01-06 | — | — | EP | claimed |
| US-7226925-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2007-06-05 | — | — | US | claimed |
| US-20040029888-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-12 | — | — | US | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-1513831-B1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB PUBL (SE) | 2010-01-06 | — | — | EP | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| US-7226925-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2007-06-05 | — | — | US | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| EP-1513831-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| US-20040029888-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-12 | — | — | US | disclosed |
| WO-2004000830-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | SYK 4613/4885AURKB 3919/4885IRAK4 4310/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | SYK 4613/4885AURKB 3919/4885IRAK4 4310/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | SYK 4613/4885AURKB 3919/4885IRAK4 4310/4885 |
| US-20040029888-A1 | Novel compounds, their use and preparation | TPH1, TPH2, HTR1A | SYK 4299/4885AURKB 3549/4885IRAK4 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.